secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2024-03-12T23:59:59+00:00
Accession:  0000950170-24-029671
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa Therapeutics appoints breast cancer specialist Dr. Tessa Cigler to board
-------------------------------------------------------------------------------

- Dr. Cigler is a medical oncologist and clinical investigator at Weill Cornell Breast Center.
- She will serve as Class II director until 2026 annual meeting and on Nominating and Governance Committee.
- Appointment effective immediately; compensation follows standard non-employee director terms.
- Company's (Z)-endoxifen program has four Phase 2 trials; two expected to readout in H2 2024.
- Dr. Cigler holds M.D. from Duke, M.P.H. from Harvard, and extensive breast cancer clinical trial experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000095017024029671/0000950170-24-029671-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000095017024029671/atos-20240309.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-029671

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer